document.write('<div id="newsmain"><table class="nftable"><tr class="nfsubhead"><TD> 2010-08-30 <A HREF=http://www.valeant.com/ target="$targ"  >Valeant Pharmaceuticals International</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530755&newsfeed_type=cat6&cusid=raucon target=_blank>GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-25 <A HREF=http://www.neuralstem.com/ target="$targ"  >NeuralStem</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530095&newsfeed_type=cat6&cusid=raucon target=_blank>Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-24 <A HREF=http://www.hemispherx.net/ target="$targ"  >Hemispherx BioPharma</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530024&newsfeed_type=cat6&cusid=raucon target=_blank>HEMISPHERX SETTLES ALL SECURITIES CLASS ACTIONS Title</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-24 <A HREF=http://www.modigenetech.com/ target="$targ"  >Modigene</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530012&newsfeed_type=cat6&cusid=raucon target=_blank>PROLOR BIOTECH RECEIVES FDA CLEARANCE FOR A PHASE II TRIAL OF ITS LONG-ACTING HUMAN GROWTH HORMONE IN THE U.S.</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-23 <A HREF=http://www.fujimed.com/ target="$targ"  >Fujifilm Medical Systems</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530143&newsfeed_type=cat6&cusid=raucon target=_blank>FUJIFILM&#8217;S FDR D-EVO&#8482; IS NOW AVAILABLE AND SHIPPING</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-23 <A HREF=http://www.tobbb.com/ target="$targ"  >to-BBB technologies</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529992&newsfeed_type=cat6&cusid=raucon target=_blank>FDA grants Orphan Drug Status for to-BBBs lead product</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-21 <A HREF=http://www.aurobindo.com/ target="$targ"  >Aurobindo Pharma</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529982&newsfeed_type=cat6&cusid=raucon target=_blank>Aurobindo Pharma receives USFDA approvals for Ampicillin for Injection</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-20 <A HREF=http://www.jazzpharmaceuticals.com/ target="$targ"  >Jazz Pharmaceuticals</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529938&newsfeed_type=cat6&cusid=raucon target=_blank>Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-19 <A HREF=http://www.optimerpharma.com/ target="$targ"  >Optimer Pharmaceuticals</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529959&newsfeed_type=cat6&cusid=raucon target=_blank>Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-19 <A HREF=http://www.acceleronpharma.com/ target="$targ"  >Acceleron Pharma</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529947&newsfeed_type=cat6&cusid=raucon target=_blank>Acceleron Pharma Receives FDA Orphan Designation for ACE-031 for the Treatment of Duchenne Muscular Dystrophy</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-19 <A HREF=http://www.gilead.com/ target="$targ"  >Gilead Sciences</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529926&newsfeed_type=cat6&cusid=raucon target=_blank>Gilead Sciences Announces Notification of ANDA Filing for Hepsera(R)</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-30 <A HREF=http://www.eisai.co.jp/index-e.html target="$targ"  >Eisai</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530701&newsfeed_type=cat6&cusid=raucon target=_blank>EISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR INVESTIGATIONAL AGENT ERIBULIN MESYLATE</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-19 <A HREF=http://www.lilly.com/ target="$targ"  >Eli Lilly</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529586&newsfeed_type=cat6&cusid=raucon target=_blank>Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta(R) to a Broader Pain Population</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-19 <A HREF=http://www.gsk.com/ target="$targ"  >GlaxoSmithKline</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529488&newsfeed_type=cat6&cusid=raucon target=_blank>GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta? (belimumab) as a potential treatment for systemic lupus erythematosus</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-19 <A HREF=http://www.hgsi.com/ target="$targ"  >Human Genome Sciences</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529487&newsfeed_type=cat6&cusid=raucon target=_blank>HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FDA PRIORITY REVIEW DESIGNATION FOR BENLYSTA? (BELIMUMAB) AS A POTENTIAL TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-19 <A HREF=http://www.pronova.com/ target="$targ"  >Pronova BioPharma</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529433&newsfeed_type=cat6&cusid=raucon target=_blank>Pronova BioPharma has received Lovaza(TM) Paragraph IV Notice Letter from Teva Pharmaceuticals</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-18 <A HREF=http://www.immunogen.com/ target="$targ"  >ImmunoGen</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529486&newsfeed_type=cat6&cusid=raucon target=_blank>ImmunoGen, Inc.Announces Orphan Drug Designation Granted to Lorvotuzumab Mertansine for Treatment of Small-Cell Lung Cancer</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-18 <A HREF=http://www.reprosrx.com/ target="$targ"  >Repros Therapeutics</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529226&newsfeed_type=cat6&cusid=raucon target=_blank>Repros Requests Type B Meeting with FDA to Discuss Phase III Protocols for Androxal</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-18 <A HREF=http://www.cslbehring.com/ target="$targ"  >CSL Behring</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529211&newsfeed_type=cat6&cusid=raucon target=_blank>CSL Behring Receives FDA Approval to Extend Shelf Life of Hizentra? from 18 Months to 24 Months</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-18 <A HREF=http://www.urigen.com/ target="$targ"  >Urigen Pharmaceuticals</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529198&newsfeed_type=cat6&cusid=raucon target=_blank>FDA Grants Urigen&#39;s URG101 Meeting</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-17 <A HREF=http://www.endocyte.com/ target="$targ"  >Endocyte</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529954&newsfeed_type=cat6&cusid=raucon target=_blank>Endocyte files registration statement with SEC for initial public offering</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-17 <A HREF=http://www.armagen.com/ target="$targ"  >ArmaGen Technologies</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=529308&newsfeed_type=cat6&cusid=raucon target=_blank>ArmaGen completes Pre-IND Meeting with FDA for AGT-181</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-27 <A HREF=http://www.roche.com/ target="$targ"  >Roche</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530673&newsfeed_type=cat6&cusid=raucon target=_blank>Roche provides update on FDA application for T-DM1</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-16 <A HREF=http://www.fda.gov/ target="$targ"  >Food and Drug Administration (FDA)</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=528936&newsfeed_type=cat6&cusid=raucon target=_blank>FDA Proposes Withdrawal of Low Blood Pressure Drug</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-16 <A HREF=http://www.teleflex.com/ target="$targ"  >Teleflex</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=528930&newsfeed_type=cat6&cusid=raucon target=_blank>Teleflex Announces Receipt of Approval of All Certificates to Foreign Governments from FDA</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-16 <A HREF=http://cticseattle.com/ target="$targ"  >Cell Therapeutics</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=528920&newsfeed_type=cat6&cusid=raucon target=_blank>EMEA Validates Cell Therapeutics, Inc.&#39;s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-16 <A HREF=http://www.mesoblast.com/ target="$targ"  >Mesoblast</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=528901&newsfeed_type=cat6&cusid=raucon target=_blank>MESOBLAST ON TRACK FOR PHASE 3 BONE MARROW TRANSPLANT TRIAL FOLLOWING POSITIVE MEETING WITH FDA</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-16 <A HREF=http://www.nanoink.net/ target="$targ"  >NanoInk</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=528898&newsfeed_type=cat6&cusid=raucon target=_blank>Oliver Yeh to Lead NanoInk&#39;s Sales Teams in Asia</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-15 <A HREF=http://www.biocancell.com/ target="$targ"  >BioCancell Therapeutics</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=528739&newsfeed_type=cat6&cusid=raucon target=_blank>BioCancell Receives Orphan Drug Approval for BC-819 as Treatment for Pancreatic Cancer</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-27 <A HREF=http://www.novartis.com/ target="$targ"  >Novartis</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530321&newsfeed_type=cat6&cusid=raucon target=_blank>Novartis receives FDA approval of Tekamlo(TM), a single-pill combination of aliskiren and amlodipine to treat high blood pressure</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-26 <A HREF=http://www.kingpharm.com/ target="$targ"  >King Pharmaceuticals</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530354&newsfeed_type=cat6&cusid=raucon target=_blank>King Pharmaceuticals Launches CYANOKIT? At Fire-Rescue International Expo</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-25 <A HREF=www.gene.com/ target="$targ"  >Genentech</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530659&newsfeed_type=cat6&cusid=raucon target=_blank>Genentech Provides Update on FDA Application for T-DM1</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-25 <A HREF=http://www.pfizer.com/main.html target="$targ"  >Pfizer</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530216&newsfeed_type=cat6&cusid=raucon target=_blank>Bristol-Myers Squibb And Pfizer Inc. Evaluate Unmet Need In Patients With Atrial Fibrillation</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-25 <A HREF=http://www.vivus.com/ target="$targ"  >VIVUS</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530162&newsfeed_type=cat6&cusid=raucon target=_blank>Data on VIVUS&#39; Qnexa(R) to Be Presented at the European Society of Cardiology Congress</A></TD></TR><tr class="nfsubhead"><TD> 2010-08-25 <A HREF=http://www.impaxlabs.com/ target="$targ"  >IMPAX Laboratories</A></TD></TR><tr class="nfsummary"><td class="nftd"><p class="nf"> <A HREF=newsfeed_news.htm?releaseid=530121&newsfeed_type=cat6&cusid=raucon target=_blank>Impax Pharmaceuticals Completes Enrollment in ADVANCE-PD Phase III Trial of IPX066 in Parkinson&#39;s Disease</A></TD></TR></TABLE></DIV>');